Autoimmune mice as models for discovery of drugs against age‐related dementia

Harbans Lal, Michael J. Forster

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

The discovery and development of drugs to treat Alzheimer's disease and other age‐associated dementias constitute an important goal of research in the pharmaceutical industry. Suitable animal models are routinely sought to expedite the discovery and development processes. The current review proposes new animal models based upon research findings from both clinical and animal investigations which suggest a neuroimmunologic component in certain age‐associated dementias. Several clinical studies are discussed which suggest associations between dementia and brain‐reactive autoantibodies in patients with Alzheimer's disease. In addition, studies of mice suggest that neuroimmunological, neuropathological, and behavioral characteristics of aging are accelerated in genetically autoimmune‐prone mice. The learning and memory deficits of autoimmune mice are qualitatively similar to those of normal aged mice, and these deficits show similar sensitivity to pharmacologic interventions involving cholinergic and GABNbenzodiazepine systems. However, the appearance and progression of these changes with age occur more rapidly and with greater reliability in the autoimmune mice when compared with non‐autoimmune strains. The studies reviewed suggest that autoimmune mice may provide a useful animal model for identification and evaluation of new drugs against learning and memory dysfunctions. In addition, the accelerated decline of learning/memory in autoimmune mice may expedite evaluation of chemical interventions designed to prevent the occurrence or arrest the progress of Alzheimer's disease and other age‐associated dementias. The autoimmune models may be especially appropriate in identifying novel drugs with the immune system as a primary target.

Original languageEnglish
Pages (from-to)1-27
Number of pages27
JournalDrug Development Research
Volume24
Issue number1
DOIs
StatePublished - 1 Jan 1991

Fingerprint

Drug Discovery
Dementia
Alzheimer Disease
Animal Models
Learning
Drug Evaluation
Memory Disorders
Drug Industry
Research
Autoantibodies
Cholinergic Agents
Immune System
Pharmaceutical Preparations

Keywords

  • Alzhelmer's disease
  • BXSB/Mpj
  • C578BL/6NNia
  • MRL/MpJ‐+
  • MRL/MpJ‐lpr
  • NZB/BINJ
  • brain‐reactive antibodies
  • drug discovery
  • habituation
  • learning
  • memory

Cite this

@article{0c5485879e1c4008a3f7edf26784d51f,
title = "Autoimmune mice as models for discovery of drugs against age‐related dementia",
abstract = "The discovery and development of drugs to treat Alzheimer's disease and other age‐associated dementias constitute an important goal of research in the pharmaceutical industry. Suitable animal models are routinely sought to expedite the discovery and development processes. The current review proposes new animal models based upon research findings from both clinical and animal investigations which suggest a neuroimmunologic component in certain age‐associated dementias. Several clinical studies are discussed which suggest associations between dementia and brain‐reactive autoantibodies in patients with Alzheimer's disease. In addition, studies of mice suggest that neuroimmunological, neuropathological, and behavioral characteristics of aging are accelerated in genetically autoimmune‐prone mice. The learning and memory deficits of autoimmune mice are qualitatively similar to those of normal aged mice, and these deficits show similar sensitivity to pharmacologic interventions involving cholinergic and GABNbenzodiazepine systems. However, the appearance and progression of these changes with age occur more rapidly and with greater reliability in the autoimmune mice when compared with non‐autoimmune strains. The studies reviewed suggest that autoimmune mice may provide a useful animal model for identification and evaluation of new drugs against learning and memory dysfunctions. In addition, the accelerated decline of learning/memory in autoimmune mice may expedite evaluation of chemical interventions designed to prevent the occurrence or arrest the progress of Alzheimer's disease and other age‐associated dementias. The autoimmune models may be especially appropriate in identifying novel drugs with the immune system as a primary target.",
keywords = "Alzhelmer's disease, BXSB/Mpj, C578BL/6NNia, MRL/MpJ‐+, MRL/MpJ‐lpr, NZB/BINJ, brain‐reactive antibodies, drug discovery, habituation, learning, memory",
author = "Harbans Lal and Forster, {Michael J.}",
year = "1991",
month = "1",
day = "1",
doi = "10.1002/ddr.430240102",
language = "English",
volume = "24",
pages = "1--27",
journal = "Drug Development Research",
issn = "0272-4391",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

Autoimmune mice as models for discovery of drugs against age‐related dementia. / Lal, Harbans; Forster, Michael J.

In: Drug Development Research, Vol. 24, No. 1, 01.01.1991, p. 1-27.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Autoimmune mice as models for discovery of drugs against age‐related dementia

AU - Lal, Harbans

AU - Forster, Michael J.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - The discovery and development of drugs to treat Alzheimer's disease and other age‐associated dementias constitute an important goal of research in the pharmaceutical industry. Suitable animal models are routinely sought to expedite the discovery and development processes. The current review proposes new animal models based upon research findings from both clinical and animal investigations which suggest a neuroimmunologic component in certain age‐associated dementias. Several clinical studies are discussed which suggest associations between dementia and brain‐reactive autoantibodies in patients with Alzheimer's disease. In addition, studies of mice suggest that neuroimmunological, neuropathological, and behavioral characteristics of aging are accelerated in genetically autoimmune‐prone mice. The learning and memory deficits of autoimmune mice are qualitatively similar to those of normal aged mice, and these deficits show similar sensitivity to pharmacologic interventions involving cholinergic and GABNbenzodiazepine systems. However, the appearance and progression of these changes with age occur more rapidly and with greater reliability in the autoimmune mice when compared with non‐autoimmune strains. The studies reviewed suggest that autoimmune mice may provide a useful animal model for identification and evaluation of new drugs against learning and memory dysfunctions. In addition, the accelerated decline of learning/memory in autoimmune mice may expedite evaluation of chemical interventions designed to prevent the occurrence or arrest the progress of Alzheimer's disease and other age‐associated dementias. The autoimmune models may be especially appropriate in identifying novel drugs with the immune system as a primary target.

AB - The discovery and development of drugs to treat Alzheimer's disease and other age‐associated dementias constitute an important goal of research in the pharmaceutical industry. Suitable animal models are routinely sought to expedite the discovery and development processes. The current review proposes new animal models based upon research findings from both clinical and animal investigations which suggest a neuroimmunologic component in certain age‐associated dementias. Several clinical studies are discussed which suggest associations between dementia and brain‐reactive autoantibodies in patients with Alzheimer's disease. In addition, studies of mice suggest that neuroimmunological, neuropathological, and behavioral characteristics of aging are accelerated in genetically autoimmune‐prone mice. The learning and memory deficits of autoimmune mice are qualitatively similar to those of normal aged mice, and these deficits show similar sensitivity to pharmacologic interventions involving cholinergic and GABNbenzodiazepine systems. However, the appearance and progression of these changes with age occur more rapidly and with greater reliability in the autoimmune mice when compared with non‐autoimmune strains. The studies reviewed suggest that autoimmune mice may provide a useful animal model for identification and evaluation of new drugs against learning and memory dysfunctions. In addition, the accelerated decline of learning/memory in autoimmune mice may expedite evaluation of chemical interventions designed to prevent the occurrence or arrest the progress of Alzheimer's disease and other age‐associated dementias. The autoimmune models may be especially appropriate in identifying novel drugs with the immune system as a primary target.

KW - Alzhelmer's disease

KW - BXSB/Mpj

KW - C578BL/6NNia

KW - MRL/MpJ‐+

KW - MRL/MpJ‐lpr

KW - NZB/BINJ

KW - brain‐reactive antibodies

KW - drug discovery

KW - habituation

KW - learning

KW - memory

UR - http://www.scopus.com/inward/record.url?scp=0025990940&partnerID=8YFLogxK

U2 - 10.1002/ddr.430240102

DO - 10.1002/ddr.430240102

M3 - Review article

AN - SCOPUS:0025990940

VL - 24

SP - 1

EP - 27

JO - Drug Development Research

JF - Drug Development Research

SN - 0272-4391

IS - 1

ER -